LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Moderna: David Rubenstein joins the Board of Directors CF
Moderna, Inc. Announces Board Changes CI
The ongoing bird flu outbreak in the United States RE
Moderna Insider Sold Shares Worth $1,842,651, According to a Recent SEC Filing MT
EU court criticizes Commission over handling of COVID vaccine contracts RE
Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing MT
China approves CSPC Pharma's RSV vaccine for clinical trials RE
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation MT
Redburn Raises Moderna's Price Target to $117 From $116 MT
Bird flu response in Michigan sparks COVID-era worry on farms RE
Moderna: partnership for mRNA vaccines in Japan CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births RE
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case MT
Moderna: grant for influenza vaccine CF
Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case RE
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion' RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Value-Defensive Index CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Defensive Index CI
Moderna: positive CHMP opinion on RSV CF
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation MT
Chart Moderna, Inc.
More charts
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna's Combination Flu, COVID-19 Shot Triggers High Immune Responses in Late-stage Study